Bicycle Therapeutics (NASDAQ:BCYC) reported quarterly losses of $(0.96) per share. This is a 62.71 percent decrease over losses of $(0.59) per share from the same period last year.
ClearSign Technologies Corporation Provides Preliminary 2023 Financial Results; Sees Q4 Revenue Of ~$1.2M
Company Expects Revenues of Approximately $1.2MM During Fourth Quarter of 2023 (Unaudited)TULSA, Okla., Feb. 7, 2024 /PRNewswire/ -- ClearSign Technologies Corporation (NASDAQ:CLIR) ("ClearSign" or the "Company"), an